文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

静脉维生素C单药治疗危重症患者:随机对照试验的系统评价与Meta分析及试验序贯分析

Intravenous vitamin C monotherapy in critically ill patients: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.
PubMed 文献 · Ann Intensive Care · 2023-03-07
一句话结论16项RCT(n=2130)显示静脉维生素C单药与总死亡率降低相关(RR 0.73,95%CI 0.60-0.89),但GRADE证据确定性低,作者认为需进一步研究确定最佳时机、剂量、疗程和人群。

该系统评价与Meta分析纳入16项RCT(n=2130)评估静脉维生素C(IVVC)单药治疗成人危重症患者,检索4个数据库至2022年6月22日,主要终点为总死亡率。结果显示IVVC单药与总死亡率显著降低相关(RR 0.73,95%CI 0.60-0.89;p=0.002;I2=42%),试验序贯分析(TSA)在相对风险降低30%和25%时支持该发现,固定效应模型敏感性分析亦支持。但GRADE评定死亡率证据确定性为低,因严重偏倚风险和不一致性。亚组分析中单中心与多中心、高剂量(≥10,000 mg/day)与低剂量、脓毒症与非脓毒症试验间无差异;事后分析中早期(<24 h)与延迟治疗、较长(>4天)与较短疗程、低偏倚风险与其他研究间亦无差异。IVVC可能在对照组死亡率高于(>37.5%;RR 0.65,95%CI 0.54-0.79)与低于(≤37.5%;RR 0.89,95%CI 0.68-1.16)中位数的试验中获益最大(亚组差异检验p=0.06),TSA支持此结果。作者认为IVVC单药可能与危重症患者死亡率获益相关,尤其在高死亡风险患者中,但证据确定性低,这一潜在救命疗法需进一步研究以确定最佳时机、剂量、疗程和获益最大的人群。

要点

  • 16项RCT(n=2130)汇总显示IVVC单药与总死亡率降低相关:RR 0.73(95%CI 0.60-0.89;p=0.002;I2=42%)。
  • GRADE评定死亡率证据确定性为低,因严重偏倚风险和不一致性。
  • TSA在相对风险降低30%和25%时支持死亡率获益,固定效应模型敏感性分析亦支持。
  • 对照组死亡率>37.5%的试验中RR 0.65(95%CI 0.54-0.79),≤37.5%的试验中RR 0.89(95%CI 0.68-1.16),亚组差异检验p=0.06,TSA支持。
  • 单中心与多中心、高剂量(≥10,000 mg/day)与低剂量、脓毒症与非脓毒症、早期(<24 h)与延迟、较长(>4天)与较短疗程、低偏倚风险与其他研究间均无差异。

适用人群与场景

  • 成人危重症患者(纳入评估静脉维生素C的随机对照试验人群)。

研究设计与关键结果

  • 研究类型:系统评价与Meta分析(含试验序贯分析),纳入16项RCT,n=2130,检索4个数据库至2022年6月22日,无语言限制。
  • 主要终点总死亡率:IVVC单药组与对照组相比RR 0.73(95%CI 0.60-0.89;p=0.002;I2=42%)。
  • TSA使用DerSimonian-Laird随机效应模型,α 5%、β 10%、相对风险降低30%、25%、20%;RRR 30%和25%时支持死亡率获益,固定效应模型敏感性分析亦支持。
  • GRADE评定死亡率证据确定性为低,因严重偏倚风险和不一致性。
  • 预设亚组分析:单中心与多中心、高剂量(≥10,000 mg/day)与低剂量、脓毒症与非脓毒症试验间无差异。
  • 事后亚组分析:早期(<24 h)与延迟治疗、较长(>4天)与较短疗程、低偏倚风险与其他研究间无差异。
  • 对照组死亡率>37.5%的试验RR 0.65(95%CI 0.54-0.79),≤37.5%的试验RR 0.89(95%CI 0.68-1.16),亚组差异检验p=0.06,TSA支持。

证据类型、等级与局限

  • 证据类型:随机对照试验的系统评价与Meta分析(含试验序贯分析),PROSPERO注册号CRD42022323880,注册日期2022年5月7日。
  • GRADE评定死亡率证据确定性为低,因严重偏倚风险和不一致性。
  • 局限:作者指出证据确定性低,需进一步研究确定最佳时机、剂量、疗程和获益最大的人群。

对床旁实践的改变

  • 作者认为IVVC单药可能与危重症患者死亡率获益相关,尤其在高死亡风险(对照组死亡率>37.5%)患者中,但证据确定性低。
  • 作者认为这一潜在救命疗法需进一步研究以确定最佳时机、剂量、疗程和获益最大的人群。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: A recent landmark randomized controlled trial (RCT) in septic patients demonstrated an increased risk of death and persistent organ dysfunction with intravenous Vitamin C (IVVC) monotherapy, which represents a disparate result from previous systematic reviews and meta-analyses (SRMA). We performed an updated SRMA of IVVC monotherapy to summarize and explore heterogeneity across current trials and conduct trial sequential analysis (TSA) to guard against type-I or type-II statistical errors.

METHODS: RCTs evaluating IVVC in adult critically ill patients were included. Four databases were searched from inception to 22 June 2022 without language restrictions. The primary outcome was overall mortality. Random effect meta-analysis was performed to estimate the pooled risk ratio. TSA for mortality was performed using the DerSimonian-Laird random effect model, alpha 5%, beta 10%, and relative risk reduction (RRR) of 30%, 25%, and 20%.

RESULTS: We included 16 RCTs (n = 2130). IVVC monotherapy is associated with significant reduction in overall mortality [risk ratio (RR) 0.73, 95% confidence interval (CI) 0.60-0.89; p = 0.002; I2 = 42%]. This finding is supported by TSA using RRR of 30% and 25%, and sensitivity analysis using fixed-effect meta-analysis. However, the certainty of our mortality finding was rated low using GRADE due to the serious risk of bias and inconsistency. In a priori subgroup analyses, we found no differences between single vs multicenter, higher (≥ 10,000 mg/day) vs lower dose and sepsis vs non-sepsis trials. Post-hoc, we found no differences in subgroup analysis of earlier (< 24 h) vs delayed treatment, longer (> 4 days) vs shorter treatment duration, and low vs other risk of bias studies. IVVC may have the greatest benefit in trials that enrolled patients above (i.e., > 37.5%; RR 0.65, 95% CI 0.54-0.79) vs below (i.e., ≤ 37.5%; RR 0.89, 95% CI 0.68-1.16) median control group mortality (test for subgroup differences: p = 0.06), and TSA supported this.

CONCLUSIONS: IVVC monotherapy may be associated with mortality benefits in critically ill patients, particularly in patients with a high risk of dying. Given the low certainty of evidence, this potentially life-saving therapy warrants further studies to identify the optimal timing, dosage, treatment duration, and patient population that will benefit most from IVVC monotherapy. PROSPERO Registration ID: CRD42022323880. Registered 7th May 2022.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Lee ZY, Ortiz-Reyes L, Lew CCH, et al. Intravenous vitamin C monotherapy in critically ill patients: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Ann Intensive Care. 2023. PMID: 36882644. doi:10.1186/s13613-023-01116-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。